| 2025年中报 | 2024年年报 | 2024年中报 | 2023年年报 | 2023年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| CDMO收入(元) | 11,641,818.36 | 41,722,766.77 | 5,120,501.42 | 52,493,429.77 | 17,275,723.70 |
| 临床服务(元) | 81,435,255.48 | 213,087,501.34 | 92,585,687.43 | 192,878,146.07 | 70,022,084.10 |
| 临床前药学研究(元) | 78,309,150.24 | 193,540,352.90 | 154,323,246.34 | 338,110,096.63 | 124,660,591.05 |
| 权益分成(元) | 4,450,807.72 | 8,495,795.57 | 4,554,144.77 | 29,626,485.56 | 16,618,529.90 |
| 自主研发技术成果转化(元) | 106,987,278.89 | 287,770,388.50 | 248,802,477.52 | 392,419,534.29 | 190,124,937.82 |
| 商业化生产(元) | 34,150,011.34 | 36,694,012.57 | 2,518,324.69 | - | - |
| 其他(元) | 15,378,790.75 | 20,612,426.57 | 17,157,152.95 | 11,920,431.18 | 5,160,217.66 |
| 营业成本(元) | |||||
| CDMO收入(元) | 7,061,361.21 | 23,100,857.40 | 2,231,238.69 | - | 9,746,493.39 |
| 临床服务(元) | 41,853,979.41 | 132,453,385.43 | 57,979,307.95 | 107,976,710.03 | 42,556,762.96 |
| 临床前药学研究(元) | 35,045,367.21 | 85,692,372.81 | 48,417,655.20 | 119,159,501.34 | 52,099,624.64 |
| 权益分成(元) | - | - | - | - | - |
| 自主研发技术成果转化(元) | 26,973,345.49 | 76,846,872.44 | 36,292,616.44 | 83,891,082.43 | 32,747,458.39 |
| 商业化生产(元) | 44,771,329.47 | 51,704,733.66 | 5,853,041.07 | - | - |
| 其他(元) | 8,029,721.99 | 15,266,191.93 | 13,295,636.02 | 9,335,257.76 | 4,593,097.69 |
| 毛利(元) | |||||
| CDMO收入(元) | 4,580,457.15 | 18,621,909.37 | 2,889,262.73 | - | 7,529,230.31 |
| 临床服务(元) | 39,581,276.07 | 80,634,115.91 | 34,606,379.48 | 84,901,436.04 | 27,465,321.14 |
| 临床前药学研究(元) | 43,263,783.03 | 107,847,980.09 | 105,905,591.14 | 218,950,595.29 | 72,560,966.41 |
| 权益分成(元) | 4,450,807.72 | 8,495,795.57 | 4,554,144.77 | - | 16,618,529.90 |
| 自主研发技术成果转化(元) | 80,013,933.40 | 210,923,516.06 | 212,509,861.08 | 308,528,451.86 | 157,377,479.43 |
| 商业化生产(元) | -10,621,318.13 | -15,010,721.09 | -3,334,716.38 | - | - |
| 其他(元) | 7,349,068.76 | 5,346,234.64 | 3,861,516.93 | 2,585,173.42 | 567,119.97 |
| 毛利率(%) | |||||
| CDMO收入(%) | 39.34 | 44.63 | 56.43 | - | 43.58 |
| 临床服务(%) | 48.60 | 37.84 | 37.38 | 44.02 | 39.22 |
| 临床前药学研究(%) | 55.25 | 55.72 | 68.63 | 64.76 | 58.21 |
| 权益分成(%) | - | - | - | - | - |
| 自主研发技术成果转化(%) | 74.79 | 73.30 | 85.41 | 78.62 | 82.78 |
| 商业化生产(%) | -31.10 | -40.91 | -132.42 | - | - |
| 其他(%) | 47.79 | 25.94 | 22.51 | 21.69 | 10.99 |
| 收入构成(%) | |||||
| CDMO收入(%) | 3.50 | 5.20 | 0.98 | 5.16 | 4.08 |
| 临床服务(%) | 24.50 | 26.57 | 17.63 | 18.96 | 16.52 |
| 临床前药学研究(%) | 23.56 | 24.13 | 29.39 | 33.23 | 29.41 |
| 权益分成(%) | 1.34 | 1.06 | 0.87 | 2.91 | 3.92 |
| 自主研发技术成果转化(%) | 32.19 | 35.89 | 47.39 | 38.57 | 44.86 |
| 商业化生产(%) | 10.28 | 4.58 | 0.48 | - | - |
| 其他(%) | 4.63 | 2.57 | 3.27 | 1.17 | 1.22 |
| 毛利构成(%) | |||||
| CDMO收入(%) | 2.72 | 4.47 | 0.80 | 0.00 | 2.67 |
| 临床服务(%) | 23.47 | 19.34 | 9.59 | 13.81 | 9.74 |
| 临床前药学研究(%) | 25.66 | 25.87 | 29.34 | 35.60 | 25.72 |
| 权益分成(%) | 2.64 | 2.04 | 1.26 | 0.00 | 5.89 |
| 自主研发技术成果转化(%) | 47.45 | 50.60 | 58.87 | 50.17 | 55.78 |
| 商业化生产(%) | -6.30 | -3.60 | -0.92 | - | - |
| 其他(%) | 4.36 | 1.28 | 1.07 | 0.42 | 0.20 |